Abstract

WITH CURRENT immunosuppressive protocols, acute rejection occurs in 30 to 70% of kidney transplant recipients, and there are data suggesting that one or more acute rejection episodes may have detrimental effects in graft survival, both in the short and long term. It is also accepted that steroid-resistant rejection may carry a worse prognosis for reversal, and that even those grafts that are rescued with antilymphocyte therapies might be fated to a short survival. The monoclonal antibody OKT3 is used for the treatment of steroid-resistant rejection in 20 to 40% of kidney transplant recipients and the short-term reversal rates are around 80 to 90%. However, the fate of OKT3rescued kidneys is less well established. We analysed graft function and survival and patient survival, in the short and long term, in patients that never had an acute rejection episode, in those with acute rejection(s) treated with highdose steroids, and in patients in whom the corticosteroids were followed by OKT3 as rescue therapy for rejection.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.